Krystal Biotech (NASDAQ:KRYS) Announces Earnings Results

Krystal Biotech (NASDAQ:KRYS) posted its earnings results on Monday. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.17), Briefing.com reports. The firm had revenue of $45.25 million for the quarter, compared to analysts’ expectations of $47.37 million. During the same period in the prior year, the business earned ($1.76) earnings per share. The company’s revenue was up 452400.0% on a year-over-year basis.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock traded down $1.70 during trading on Tuesday, hitting $155.24. 79,497 shares of the company’s stock were exchanged, compared to its average volume of 361,948. The business has a 50-day simple moving average of $169.04 and a 200-day simple moving average of $133.73. Krystal Biotech has a 52-week low of $83.38 and a 52-week high of $189.97. The stock has a market capitalization of $4.43 billion, a price-to-earnings ratio of 1,957.99 and a beta of 0.91.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Citigroup upped their target price on Krystal Biotech from $160.00 to $195.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Guggenheim lifted their target price on Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. HC Wainwright restated a “buy” rating and set a $200.00 price target on shares of Krystal Biotech in a research report on Monday. William Blair restated an “outperform” rating on shares of Krystal Biotech in a research note on Tuesday, February 27th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $204.00 price target (up previously from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, Krystal Biotech has a consensus rating of “Buy” and an average target price of $171.00.

Insiders Place Their Bets

In other Krystal Biotech news, CAO Kathryn Romano sold 8,087 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $136.91, for a total value of $1,107,191.17. Following the completion of the sale, the chief accounting officer now owns 12,556 shares in the company, valued at approximately $1,719,041.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CAO Kathryn Romano sold 8,087 shares of Krystal Biotech stock in a transaction on Monday, February 26th. The stock was sold at an average price of $136.91, for a total value of $1,107,191.17. Following the completion of the transaction, the chief accounting officer now directly owns 12,556 shares in the company, valued at $1,719,041.96. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the sale, the insider now directly owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,087 shares of company stock worth $6,210,591. 14.10% of the stock is owned by corporate insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).